Loading clinical trials...

A Registry of AL Amyloidosis (ReAL) | Clinical Trials | Clareo Health

RECRUITING

A Registry of AL Amyloidosis (ReAL)

A Registry to Investigate Real-world Natural History, Impact of Therapies and Patterns of Progression of AL Amyloidosis (ReAL)

NCT04839003•Fondazione IRCCS Policlinico San Matteo di Pavia

View on ClinicalTrials.gov

Summary

The purpose of this protocol is to generate a large registry of patients with AL amyloidosis.

Detailed Description

Thanks to this registry, it will be possible to collect data at diagnosis and during follow up, in order to be able to describe the natural history of AL amyloidosis in a real-world setting and to define and validate prognostic models, response and relapse criteria applicable at any point of the disease.

Eligibility

Age

18 - 99 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. diagnosis of systemic AL amyloidosis;
•2. treatment-naïve (pre-treatment data collected at participating center available for retrospective part);
•3. age ≥18 years;
•4. ability to understand and willingness to sign an informed consent (patients who already sign informed consent for clinical data to be used in retrospective analyses will be accepted);
•5. planned (or ongoing) follow-up at participating center.

Exclusion Criteria

•1. non-AL amyloidosis;
•2. previous treatment for AL amyloidosis.

Locations (1)

Fondazione IRCCS Policlinico San Matteo

Pavia, Italy

Key Dates

Start Date

February 27, 2020

Primary Completion Date

May 1, 2025

Completion Date

May 1, 2025

Last Updated

November 25, 2024

Enrollment

5,000

ESTIMATED participants

Conditions

AL Amyloidosis

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

NCT06192979

Amyloidosis; SystemicAL Amyloidosis

View study

RECRUITINGPHASE1

Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

NCT07250269

Relapsed/Refractory AL Amyloidosis

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 25, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Registry of AL Amyloidosis (ReAL)

Inclusion Criteria

Exclusion Criteria

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy

National Registry of Rare Kidney Diseases

Multimodal Radiomics Model (18F-FAPI PET/CT + CMR) for AL Cardiac Amyloidosis Prognosis

Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis